The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Open accessAbstract
BACKGROUND: Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma. METHODS: We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Patients were randomly assigned to receive one of the two regimens, followed by maintenance monotherapy with rituximab. Treatment with rituximab plus lenalidomide consisted of 18 cycles of the two drugs, followed by rituximab maintenance therapy every 8 weeks for 12 cycles (six additional doses). Treatment with rituximab plus chemotherapy consisted of the investigator's choice of one of three rituximab-based regimens, followed by maintenance monotherapy with rituximab every 8 weeks for 12 cycles. The primary end points were complete response (confirmed or unconfirmed) at 120 weeks and progression-free survival. RESULTS: A total of 1030 patients were randomly assigned to receive rituximab plus lenalidomide (513 patients) or rituximab plus chemotherapy (517 patients). The rate of confirmed or unconfirmed complete response at 120 weeks was similar in the two groups: 48% (95% confidence interval [CI], 44 to 53) in the rituximab-lenalidomide group and 53% (95% CI, 49 to 57) in the rituximab-chemotherapy group (P=0.13). The interim 3-year rate of progression-free survival was 77% (95% CI, 72 to 80) and 78% (95% CI, 74 to 82), respectively. A higher percentage of patients in the rituximab-chemotherapy group had grade 3 or 4 neutropenia (32% vs. 50%) and febrile neutropenia of any grade (2% vs. 7%), and a higher percentage of patients in the rituximab-lenalidomide group had grade 3 or 4 cutaneous reactions (7% vs. 1%). CONCLUSIONS: Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and rituximab plus chemotherapy (with both regimens followed by rituximab maintenance therapy). The safety profile differed in the two groups. (Funded by Celgene; RELEVANCE ClinicalTrials.gov numbers, NCT01476787 and NCT01650701 , and EudraCT number, 2011-002792-42 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, patients with R/R chronic lymphocytic leukaemia (CLL) receiving R2 have a ORR of >65%78”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
Rummel, M., Niederle, N., Maschmeyer, G., Banat, G.-A., von Grünhagen, U., Losem, C. J., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,512
Salles, G., Seymour, J. F., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,075
Self-citationSmith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3488 · Cited by 907
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R. E., Davies, A. J., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E. H., Sangha, R. S., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 824
Self-citationLopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
Brice, P., Bastion, Y., Lepage, É., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah-Fisch, I. M., & Solal‐Céligny, P. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1110 · Cited by 646
Self-citationFlinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., Macdonald, D. A., Hertzberg, M., Kwan, Y., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 644
Self-citationGandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Flagged first, then by citations
Research works printed but not linked: 1
- Fowler N. Extended dosing lenalidomide with intensified rituximab in untreated indolent NHL. Hematol Oncol 2015;33:200-201. poster.
Cited by
Sorted by citations
Items 301–373 of 373
Upfront Lenalidomide in Follicular Lymphoma: Time has Come or Not?
Garg, V., Gogia, A., & Gupta, G. (2018) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-018-1046-6
Lockmer, S., Østenstad, B., Hagberg, H., Holte, H., Wahlin, B. E., Wader, K. F., Smedby, K. E. E., Brown, P., & Kimby, E. K. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02362
Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab
Barr, P. M. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00419
Lenalidomid beim follikulären Lymphom
Behrend, C. (2019) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-019-6483-3
Salles, G. (2019) · Hematological Oncology · doi:10.1002/hon.2599
Self-citationTreatment of high‐risk follicular lymphoma
Jurczak, W. J. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000230
Chemotherapiefreie Therapie in der Erstlinie beim follikulären Lymphom
Behrend, C., & Finke, J. (2019) · Im Focus Onkologie · doi:10.1007/s15015-019-0101-y
Will GALEN become more RELEVANT?
von Keudell, G., & Younes, A. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30136-x
Chemotherapiefreie Behandlung indolenter Lymphome: Hype oder Hope?
Viardot, A., & Heß, G. (2019) · Der Onkologe · doi:10.1007/s00761-019-0633-y
Lenalidomid/Rituximab in der Behandlung indolenter Non-Hodgkin-Lymphome
Herold, M. J. (2019) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-019-6655-1
Palmieri, R., Esposito, F., Meconi, F., Rapisarda, V. M., Anemona, L., Paterno, G., Vaccarini, S., Nasso, D., Pupo, L., & Cantonetti, M. (2019) · Case Reports in Hematology · doi:10.1155/2019/2845130
Targeting the Tumor Microenvironment
Strati, P., Fowler, N. H., & Fountain, E. (2019) · Springer eBooks · doi:10.1007/978-3-030-26211-2_12
Self-citationNovel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma
Chin, C. K., & Nastoupil, L. J. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.03.002
Liu, J., Stewart, D. A., Fontaine, A., Peters, A., Fleury, I., Mollica, L. R., Prica, A. A., Buckstein, R. J., Sehn, L. H., Jiang, A., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1772472
Self-citationFollicular Lymphoma: Therapeutics and Management
Smith, A. H., Emery, L. P., & Lansigan, F. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49741-5_5
Current therapy for indolent lymphomas
Duffles, G., Delamain, M. T., & Souza, C. A. D. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.09.007
Overuren en overwerktoeslagen van deeltijders; a ' continuing story' ' of een nieuwe wending?
Burri, S. D. (2008) · Nederlands tijdschrift voor Europees recht
Soubeyran, P. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_780
Habermann, T. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00059-3
Soubeyran, P. (2021) · Springer eBooks · doi:10.1007/978-3-319-69892-2_780-1
Moccia, A. A., Dreyling, M. H., & Ghielmini, M. E. G. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-55989-2_6
Hematological Cancer in Older Adults with Frailty
Goede, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-89162-6_27
Sun, S., Fulati, W., Shen, L., Wu, M., Huang, Z., Qian, W., Chen, P., Hu, Y., Chen, M., Xu, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1524082/v1
Sun, S., Fulati, W., Shen, L., Wu, M., Huang, Z., Qian, W., Chen, P., Hu, Y., Chen, M., Xu, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1524082/v2
Moving towards the chemo-free treatment of lymphoma: hype or reality?
Cheson, B. D. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.153
Song, C., Feng, Y., Ge, F.-M., Zhang, Z., & Su, B. (2022) · PubMed Central
Freedman, A. S., & LaCasce, A. S. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm120.pub2
Park, C. H., & Choi, Y. B. (2022) · Imsang soa hyeoraek jong-yang/Imsang soa hyeol'aeg jong'yang/Clinical pediatric hematology-oncology · doi:10.15264/cpho.2022.29.2.79
Fricker, J. (2019) · EMJ Hematology · doi:10.33590/emjhematol/10314634
Tuscano, J. M., Poh, C., Kaesberg, P. R., Luxardi, G., Merleev, A. A., Marusina, A. I., Brunson, A. M., Rosenberg, A., Jonas, B. A., & Maverakis, E. M. (2023) · doi:10.1158/1078-0432.c.6530610
Tuscano, J. M., Poh, C., Kaesberg, P. R., Luxardi, G., Merleev, A. A., Marusina, A. I., Brunson, A. M., Rosenberg, A., Jonas, B. A., & Maverakis, E. M. (2023) · doi:10.1158/1078-0432.c.6530610.v1
The Biological Basis for Targeting Protein Turnover in Malignant Cells
Orlowski, R. Z. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch22
Clinical Experience with Pro‐Apoptotic Agents
Lew, T. E., & Seymour, J. F. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch12
Moving beyond chemotherapy in the management of follicular lymphoma
Kridel, R. (2022) · Canadian Hematology Today · doi:10.58931/cht.2022.1316
Management of follicular lymphoma at first relapse
Kansara, R. R. (2022) · Canadian Hematology Today · doi:10.58931/cht.2022.116
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma
Dong, N. C., Pérez‐Lamas, L., & Chávez, J. C. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2250722
Zhang, Q., Feng, J., Wang, H., Huang, H., Zhang, H., Li, X., Gao, Y., Song, Y., Li, Z., Bai, O., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00063-8
Richardson, D. R., & Mulroney, C. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-38058-7_2
Zertifizierte Fortbildung: Follikuläres Lymphom – Pathogenese, Diagnostik und Therapie
Adolph, L., & Weigert, O. (2023) · Trillium Krebsmedizin · doi:10.47184/tk.2023.07-08.4
Moccia, A. A., Dreyling, M. H., & Ghielmini, M. E. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-22881-0_6
Hill, B. T., Chen, Y., Jagadeesh, D., Dean, R. M., Koç, O. N., Boughan, K. M., Cooper, B., Pohlman, B. L., Caimi, P. F., & Smith, M. R. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2325636
Planken, S., Faict, S., Trullemans, F., Linskens, E. A., Vandepoele, K., & Becker, A. D. (2024) · Cureus · doi:10.7759/cureus.66291
Targeted protein degradation using thalidomide and its derivatives
Yamanaka, S. (2024) · Translational and Regulatory Sciences · doi:10.33611/trs.2024-007
A phase 2 study of frontline pembrolizumab in follicular lymphoma
Ho, C., Zhu, S., Gooley, T., Gujral, T. S., Lynch, R. C., Poh, C., Shadman, M. S., Smith, S. D., Tseng, Y. D., & Gopal, A. K. (2024) · eJHaem · doi:10.1002/jha2.1029
Wang, N., Huang, X., Jiang, X., Wang, L., Cheng, S., Xu, P., Dong, L., Ou‐Yang, B., Mu, R., Li, C., et al. (2024) · Hematological Oncology · doi:10.1002/hon.70012
Othman, T. A., Marquez-Arreguin, G., Esteghamat, N., & Tuscano, J. M. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2443552
Molekular zielgerichtete Therapien – brauchen wir überhaupt noch Chemotherapie?
Hellmuth, J. C., Koch, R., & Weigert, O. (2025) · Angewandte Nuklearmedizin · doi:10.1055/a-2405-3314
Whipple's disease in a patient with follicular lymphoma
Ashley, P., Strati, P., Taherian, M., Mulanovich, V. E., & Ariza‐Heredia, E. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.116783
Fujii, S., Sugino, N., & Miura, Y. (2025) · Stem Cells and Development · doi:10.1089/scd.2025.0022
Molekular zielgerichtete Therapien – brauchen wir überhaupt noch Chemotherapie?
Hellmuth, J. C., Koch, R., & Weigert, O. (2025) · TumorDiagnostik & Therapie · doi:10.1055/a-2567-3231
Kashyap, S., Sankhala, E., Huang, I., Liu, S., Imani, A., Heeter, J., Blekherman, M., Lawson, M., Hang, B. I., & Sankhala, K. K. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5259668
Hirano, S., Hanada, K., & Maeda, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-05053-6
Masson, M. (2025) · Revue du Rhumatisme · doi:10.1016/j.rhum.2025.06.015
Kashyap, S., Sankhala, E., Huang, I., Liu, S., Imani, A., Heeter, J., Blekherman, M., Lawson, M., Hang, B. I., & Sankhala, K. K. (2025) · Research Square · doi:10.21203/rs.3.rs-6827215/v1
Chemokine Receptor Profiles as Predictors of Survival and Early Progression in Follicular Lymphoma
Zupo, A., Pansy, K., Gaksch, L., Waldhart, J., Brunner, A., Strobl, J., Szmyra, M., Haingartner, S., Tomazic, P. V., Greinix, H. T., et al. (2025) · eJHaem · doi:10.1002/jha2.70131
EXABS-219-IBCL: Follicular Lymphoma: Does the Choice of Frontline Treatment Matter?
Akkad, N., & Flowers, C. R. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(25)00355-6
EXABS-221-IBCL: Novel Immunotherapy Combinations in Indolent Lymphoma
Geva, M., & Falchi, L. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(25)00356-8
Unstacking the deck in follicular lymphoma clinical trials
Yamshon, S., & Leonard, J. P. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf231
Hesius, E. A. M., Stewart, P., Kroeze, L. I., van der Spek, E., Issa, D. E., Nooijen, P. T. G. A., Luijks, J. A. C. W., de Castro, D. G., Groenen, P. J. T. A., van Spriel, A. B., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2556177
The emerging role of tafasitamab in follicular lymphoma
Lazic, T., Barbieri, E., & Luminari, S. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2560083
Pelliccia, S., Banchi, M., Marchi, L. D., Cencini, E., Seimonte, C., Fabbri, A., Nunzi, A., Destefano, S., Bocci, G., & Cox, M. C. (2026) · Cancers · doi:10.3390/cancers18020347
Brisou, G. (2020) · theses.fr (ABES) · doi:10.70675/0b7366f2z1264z4d83z8f28z435932a47a1a
Identification de nouvelles pistes de ciblage thérapeutique dans le lymphome folliculaire
Rossi, C. (2018) · theses.fr (ABES) · doi:10.70675/816b7c32z8a55z4ebczb2e2zc6f6dc3a248a
Modélisation de la réponse thérapeutique du lymphome folliculaire grâce à un modèle 3D organoïde
Houmera, N. (2023) · theses.fr (ABES) · doi:10.70675/08a3ce75z28fdz46aez9027z117136acf989
Thakkar, K., Ismail, B., & Greene, J. N. (2026) · Cureus · doi:10.7759/cureus.107125
Odronextamab: a bispecific antibody for follicular lymphoma
García-Sancho, A. M., Cabero-Martínez, A., & Gutiérrez, N. C. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2689652
Negara, I., Arnaut, O., & Buruiana, S. (2026) · Moldovan Journal of Health Sciences · doi:10.52645/mjhs.2026.2.11
Lynch, R. C., Poh, C., Shadman, M. S., Till, B. G., Di, M., Ujjani, C. S., Raghunathan, V. M., Smith, S. D., Maloney, D. G., Gausman, D., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02906
Pirosa, M. C., Brodtkorb, M., Schär, S., Wahlin, B. E., Hernberg, M., Pedersen, M., Stathis, A., Zander, T., Novak, U., Zenz, T., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70801
Katano, A. (2026) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj-d-26-00174
Ladetto, M., Bolaños, N., Bouguet, G., Herfarth, K. K., Hiddemann, W., Leppä, S., Linton, K., López‐Guillermo, A., Luminari, S., Morschhauser, F., et al. (2026) · HemaSphere · doi:10.1002/hem3.70507
Self-citationGalušić, D., Živković, N., Bašić‐Kinda, S., Dreta, B., Ivić, M., Dujmović, D., Morić-Perić, M., Holik, H., Franjić, N., Sinčić-Petričević, J., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19101640
Metadata
- Authors
- Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., Haioun, C., Maisonneuve, H., Ysebaert, L., Bartlett, N. L., Bouabdallah, K., Brice, P., Ribrag, V., Daguindau, N., Le Gouill, S., Pica, G. M., Martin Garcia-Sancho, A., López-Guillermo, A., Larouche, J.-F., Ando, K., Gomes da Silva, M., André, M., Zachée, P., Sehn, L. H., Tobinai, K., Cartron, G., Liu, D., Wang, J., Xerri, L., & Salles, G. A.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d’Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and...
- ORCID
- Morschhauser, Franck
- Fowler, Nathan H.
- Feugier, Pierre
- Tilly, Hervé
- Palomba, M. Lia
- Fruchart, Christophe
- Flinn, Ian W.
- Bartlett, Nancy L.
- Bouabdallah, Kamal
- Brice, Pauline
- Ribrag, Vincent
- Larouche, Jean-François
- Ando, Kiyoshi
- André, Marc
- Zachée, Pierre
- Sehn, Laurie H.
- Tobinai, Kensei
- Cartron, Guillaume
- Wang, Jianming
- Xerri, Luc
- Salles, Gilles A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-09-06
- Volume
- 379
- Issue
- 10
- Pages
- 934-947
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11003525
- OpenAlex
- W2891543930
- Cited by
- 373
- References
- 30
- Citations by year
- 2026: 17 · 2025: 52 · 2024: 38 · 2023: 37 · 2022: 52 · 2021: 62 · 2020: 58 · 2019: 51 · 2018: 5
- FWCI
- 33.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Funders
- Celgene
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- follicular lymphoma, rituximab, lenalidomide, previously untreated lymphoma, rituximab plus chemotherapy, maintenance therapy, complete response, progression-free survival, neutropenia, skin reactions, immunomodulatory therapy, B-cell non-Hodgkin lymphoma, safety and tolerability
- MeSH terms
- Rituximab, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neutropenia, Skin Diseases, Thalidomide, Survival Rate, Disease-Free Survival, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
